Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.33 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.33 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041034 | 0.94 | LMNA (0.54) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL14958965 | 0.94 | LMNA (0.54) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL7995861 | 0.93 | LMNA (0.55) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL23188236 | 0.93 | LMNA (0.53) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL7052588 | 0.91 | LMNA (0.53) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL18850090 | 0.91 | LMNA (0.52) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL24251818 | 0.90 | LMNA (0.48) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL24251813 | 0.90 | LMNA (0.48) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL9009053 | 0.89 | LMNA (0.58) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL18850180 | 0.89 | LMNA (0.50) | LMNACYP2C19HIF1AEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445725-B2 | Process for the preparation of iosimenol | MALLINCKRODT LLC (US) | 2013-05-21 | — | — | US | claimed |
| EP-2240432-B1 | PROCESS FOR THE PREPARATION OF IOSIMENOL | MALLINCKRODT LLC (US) | 2012-07-04 | — | — | EP | claimed |
| US-20100280270-A1 | Process for the Prepartion of Iosimenol | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2010-11-04 | — | — | US | claimed |
| EP-2240432-A1 | PROCESS FOR THE PREPARATION OF IOSIMENOL | Mallinckrodt Inc. (US) | 2010-10-20 | — | — | EP | claimed |
| WO-2009091758-A1 | PROCESS FOR THE PREPARATION OF IOSIMENOL | MALLINCKRODT INC. (US) | 2009-07-23 | — | — | WO | claimed |
| US-20220048852-A1 | PROCESS OF PREPARING IOSIMENOL | OTSUKA PHARMA CO LTD (JP) | 2022-02-17 | — | — | US | disclosed |
| US-20220048852-A1 | PROCESS OF PREPARING IOSIMENOL | OTSUKA PHARMA CO LTD (JP) | 2022-02-17 | — | — | US | disclosed |
| EP-3371147-B1 | INNOVATIVE PREPARATION AND CRYSTALLIZATION OF IOSIMENOL | OTSUKA PHARMA CO LTD (JP) | 2021-04-07 | — | — | EP | disclosed |
| US-20200095191-A1 | PROCESS OF PREPARING IOSIMENOL | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-26 | — | — | US | disclosed |
| EP-3619192-A1 | PROCESS OF PREPARING IOSIMENOL | Otsuka Pharmaceutical Co., Ltd. (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-10544089-B2 | Innovative preparation and crystallization of iosimenol | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-01-28 | — | — | US | disclosed |
| US-10544089-B2 | Innovative preparation and crystallization of iosimenol | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-01-28 | — | — | US | disclosed |
| US-8445725-B2 | Process for the preparation of iosimenol | MALLINCKRODT LLC (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445725-B2 | Process for the preparation of iosimenol | MALLINCKRODT LLC (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2240432-B1 | PROCESS FOR THE PREPARATION OF IOSIMENOL | MALLINCKRODT LLC (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20100280270-A1 | Process for the Prepartion of Iosimenol | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2010-11-04 | — | — | US | disclosed |
| US-20100280270-A1 | Process for the Prepartion of Iosimenol | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2010-11-04 | — | — | US | disclosed |
| US-20100280270-A1 | Process for the Prepartion of Iosimenol | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2010-11-04 | — | — | US | disclosed |
| EP-2240432-A1 | PROCESS FOR THE PREPARATION OF IOSIMENOL | Mallinckrodt Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009091758-A1 | PROCESS FOR THE PREPARATION OF IOSIMENOL | MALLINCKRODT INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544089-B2 | Innovative preparation and crystallization of iosimenol | CYP17A1, CYP46A1, CYP19A1 | LMNA 1760/4885CYP2C19 181/4885HIF1A 4525/4885 |
| US-20200095191-A1 | PROCESS OF PREPARING IOSIMENOL | AOC2, SSTR5, SSTR2 | LMNA 2553/4885CYP2C19 1343/4885HIF1A 3152/4885 |
| US-20100280270-A1 | Process for the Prepartion of Iosimenol | DHCR24, DRD4, NONO | LMNA 713/4885CYP2C19 1552/4885HIF1A 2931/4885 |
| US-20220048852-A1 | PROCESS OF PREPARING IOSIMENOL | AOC2, SSTR2, NISCH | LMNA 3153/4885CYP2C19 1827/4885HIF1A 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.